Ginkgo Bioworks Holdings (DNA) EBT Margin (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly EBT Margin came in at 390.98% in Q1 2026, down 17329.0% YoY from N/an in Q1 2025, and down 60.42% on a QoQ basis from 243.72% in Q4 2025.
Ginkgo Bioworks Holdings (DNA) EBT Margin (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of EBT Margin data on file, last reported at 390.98% in Q1 2026.
- Quarterly EBT Margin fell 17329.0% year-over-year to 390.98% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 211.5% (down 701.0% YoY) and the FY2025 annual result came in at 184.3%, up 5684.0% from the prior year.
- EBT Margin slipped to 390.98% in Q1 2026, from 243.72% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 63.76% in Q3 2024 to a low of 1009.31% in Q3 2022.
- A 5-year average of 319.66% and a median of 245.99% in 2024 frame the typical range for EBT Margin.
- The widest YoY moves for EBT Margin: up 89018 bps in 2022, down 87709 bps in 2022.
- Tracing DNA's EBT Margin over 5 years: stood at 191.13% in 2022, then soared by 54 bps to 87.17% in 2023, then plunged by 182 bps to 245.99% in 2024, then rose by 1 bps to 243.72% in 2025, then tumbled by 60 bps to 390.98% in 2026.
- The last three EBT Margin figures came in at 390.98% (Q1 2026), 243.72% (Q4 2025), and 207.93% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | -283.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -283.75% |
| Mar 31, 2026 | -390.98% |
| Dec 31, 2025 | -243.72% |
| Sep 30, 2025 | -207.93% |
| Jun 30, 2025 | -122.13% |
| Mar 31, 2025 | -217.69% |
| Dec 31, 2024 | -245.99% |
| Sep 30, 2024 | -63.76% |
| Jun 30, 2024 | -386.06% |
| Mar 31, 2024 | -437.17% |
| Dec 31, 2023 | -87.17% |
| Sep 30, 2023 | -546.48% |
| Jun 30, 2023 | -215.03% |
| Mar 31, 2023 | -253.88% |
| Dec 31, 2022 | -191.13% |
| Sep 30, 2022 | -1,009.31% |
| Jun 30, 2022 | -463.71% |
| Mar 31, 2022 | -351.99% |
| Dec 31, 2021 | -1,081.31% |
| Sep 30, 2021 | -132.21% |